# Telix Pharmaceuticals (Innovations) Pty trials: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor, 8 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Telix Pharmaceuticals (Innovations) Pty Limited: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/telix-pharmaceuticals-innovations-pty-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931261 | \[18F\]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Not yet recruiting | Brain Metastasis, Radiation Necrosis, Pseudoprogression, Tumor Progression | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931261) |
| October 13, 2026 | NCT07870746 | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | Not yet recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870746) |
| November 20, 2025 | NCT07238322 | \[18F\]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes | Telix Pharmaceuticals (Innovations) Pty Limited | Observational | Completed | Retrospective Study, Glioma, Brain Neoplasms | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238322) |
| September 29, 2025 | NCT07197645 | Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 | Recruiting | Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197645) |
| September 29, 2025 | NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197580) |
| August 3, 2025 | NCT07100730 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Recruiting | Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform, Glioblastoma Multiforme, Adult... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07100730) |
| July 4, 2025 | NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Active not recruiting | PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography... | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052214) |
| December 27, 2024 | NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Recruiting | Clear Cell Renal Cell Carcinoma | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06750419) |
| December 19, 2024 | NCT06743100 | 18F-Floretyrosine Expanded Access Program | Telix Pharmaceuticals (Innovations) Pty Limited | Not applicable | No longer available | Glioma (Any Grade) in the Brain | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06743100) |
| October 23, 2024 | NCT06655064 | Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations | Telix Pharmaceuticals (Innovations) Pty Limited | Observational | Terminated | Prostate Cancer (Adenocarcinoma) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06655064) |
| July 25, 2024 | NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06520345) |
| October 19, 2023 | NCT06090331 | 89Zr-DFO-girentuximab Expanded Access Program (EAP) | Telix Pharmaceuticals (Innovations) Pty Limited | Not applicable | No longer available | Clear Cell Renal Cell Carcinoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06090331) |
| May 22, 2023 | NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 | Recruiting | Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05868174) |
| May 17, 2023 | NCT05861778 | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 | Completed | Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05861778) |
| May 6, 2023 | NCT05847348 | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Unknown | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05847348) |
| July 11, 2022 | NCT05450744 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 | Active not recruiting | Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05450744) |
| December 7, 2021 | NCT05146973 | External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | Completed | Prostate Cancer | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05146973) |
| March 8, 2021 | NCT04786847 | 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 | Completed | Metastatic Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04786847) |
| January 27, 2021 | NCT04726033 | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) | Telix Pharmaceuticals (Innovations) Pty Limited | Early phase 1 | Completed | Metastatic Prostate Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04726033) |
| August 3, 2020 | NCT04496089 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 | Completed | Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04496089) |
| February 21, 2019 | NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Completed | Clear Cell Renal Cell Carcinoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849118) |
| February 21, 2019 | NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1/2 | Completed | Glioblastoma Multiforme | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849105) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 8 |
| Not applicable | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 8 |
| Recruiting | 6 |
| No longer available | 2 |
| Not yet recruiting | 2 |
| Active not recruiting | 2 |
| Unknown | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Prostatic Neoplasms | 7 |
| Carcinoma, Renal Cell | 7 |
| Glioblastoma | 3 |
| Brain Neoplasms | 3 |
| Neoplasms | 2 |
| Kidney Neoplasms | 2 |
| Recurrence | 2 |
| Glioma | 2 |
| Neoplasm Recurrence, Local | 1 |
| Central Nervous System Neoplasms | 1 |
| Disease Progression | 1 |
| Bone Neoplasms | 1 |
| Adenocarcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
- [Smoothie and juice bars in the United States](https://specstream.ai/data/businesses/smoothie-and-juice-bars/united-states)
- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
